Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Appoints Matthew J. Pietras as CFO and COO
View:
Post by Betteryear2 on Aug 03, 2021 7:30am

Appoints Matthew J. Pietras as CFO and COO

TORONTO, ON / ACCESSWIRE / August 3, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today announced that Matthew J. Pietras has been appointed as Chief Financial Officer and Chief Operating Officer, effective August 28, 2021. Pietras was most recently Vice President of Finance at CiVi Biopharma. Carl Solomon, StageZero's interim CFO has announced his resignation and will step down August 28, 2021.

In addition to leading the finance function, including oversight of accounting, financial reporting analysis and controls, treasury and investor relations, Pietras will head StageZero's operations, including its U.S. lab in Richmond, Virginia. Pietras will be based in Washington D.C., near the U.S. lab, and will report to Chief Executive Officer James R. Howard-Tripp.

"Hiring an accomplished life sciences executive such as Matt as a full-time CFO and COO is a milestone accomplishment for StageZero," said Howard-Tripp. "Matt has comprehensive technical accounting, finance, governance, capital raising, and regulatory expertise, along with an extensive background in life sciences. This combination will be a valuable asset as we advance StageZero as a commercial-stage healthcare solutions company."

"We are expanding our management team and board of directors to build a larger enterprise as we pursue our mission of reducing late-stage disease diagnosis through early detection and delivering personalized health management through telehealth. We are thrilled that Matt is joining the team and look forward to his contributions," said Howard-Tripp. "At the same time, we want to very much thank Carl for all of his guidance and efforts during what has been an important phase in the Company's development."

"StageZero Life Sciences is at an exciting and important turning point in its history," said Pietras. "The planned acquisition and integration of Care Oncology promises to be transformative and will provide the Company with multiple revenue streams. I am looking forward to leveraging my financial and operational experience to help the management team position StageZero Life Sciences for long-term growth and profitability."

Pietras brings two decades of financial executive experience, primarily at life science companies. Prior to joining StageZero Life Sciences, he was Vice President of Finance at Maryland-based CiVi Biopharma, where he was responsible for the oversight of Finance and Operations. Prior to that, he was Corporate Treasurer and Controller of Viela Bio from 2017 through 2019. At Viela Bio, the spin-out of AstraZeneca's AutoImmune Franchise, he was responsible for the design and implementation of the financial operations and preparing the company for its eventual IPO. From 2013 through 2017, he held senior finance roles at AstraZeneca/Medimmune, culminating in his position as Global Therapeutic Area Finance Director for the company's Oncology portfolio. He also held finance roles at Wells Fargo, Wachovia, and KPMG. He holds a B.S. in accounting and a B.S. in international business from Pennsylvania State University, and an M.S. in biotechnology and an MBA from Johns Hopkins University. Pietras is also a Certified Public Accountant.

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company's next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.

Comment by davewho on Aug 03, 2021 8:21am
sounds like a very experienced addition to SZLS management team. More to come. "StageZero Life Sciences is at an exciting and important turning point in its history," said Pietras. "The planned acquisition and integration of Care Oncology promises to be transformative and will provide the Company with multiple revenue streams. I am looking forward to leveraging my financial and ...more  
Comment by LithLover on Aug 03, 2021 1:34pm
Nice!! "We are expanding our management team and board of directors to build a larger enterprise as we pursue our mission of reducing late-stage disease diagnosis through early detection and delivering personalized health management through telehealth "StageZero Life Sciences is at an exciting and important turning point in its history," said Pietras. "The planned ...more  
Comment by MUTDMUTD on Aug 04, 2021 9:06am
... happy to finally see the CEO loosening his hold on SZLS and bringing in others to run the operations... no longer a "one person" show with JHT doing everything... hoping this is the "TSN turning point to pull SZLS out of the misery of what is clearly a Stage 4 chart pattern based on technical analysis... and to develop into a Stage 1 then quickly into a Stage 2 chart pattern so ...more  
Comment by Mykndrsn on Aug 04, 2021 9:26am
The Care acquisition will bring an infusion of talent to SZLS as well.
Comment by MUTDMUTD on Aug 04, 2021 9:35am
I hope you are right... one person was never going to take SZLS to becoming, as the CEO has stated publicly, a multi billion dollar company... All IMO. DYODD.
Comment by capebretongirl on Aug 04, 2021 9:42am
Bottom line is that we will need an infusion of clients seeking cancer diagnosis/treatment to replace the covid revenue which will dwindle away. Fresh thiking on the SZ board will not hurt this cause but revenue will determine the future of this company and right now its al about CARE and telehealth.  
Comment by Mykndrsn on Aug 04, 2021 9:49am
Care comes with vertical integration and multiple revenue streams. Covid testing will quickly become a sideline business.
Comment by LithLover on Aug 04, 2021 10:14am
In The Q & A Rebecca states that additional board members/directors will be brought on with the closing of the deal.  "The Board of SZLS will undergo significant change over the next few months. The addition of Health Clinics/Care Oncology Directors will occur after the acquisition has closed. In addition to this, SZLS is intending to ensure the Board is fully reflective of the ...more  
Comment by MUTDMUTD on Aug 04, 2021 10:24am
... Lith, you'll have to excuse me when I say to you ... I'll believe it when I see it... thankfully I am seeing a new CFO/COO, so that's a start... All IMO. DYODD.
Comment by TrippinAgain91 on Aug 04, 2021 11:22am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities